Equity
Additional Paid-In Capital
Vertex Pharmaceuticals Additional Paid-In Capital increased by 2.1% to $5.12B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 23.3%, from $6.67B to $5.12B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows a downward trend with a -8.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ4 2025
How to read this metric
An increase typically signals recent equity financing activities or the issuance of shares for employee compensation.
Detailed definition
Additional paid-in capital represents the amount of capital received from investors in excess of the par value of the is...
Peer comparison
Common in all corporations; levels depend on the history of equity issuance and stock-based compensation.
Metric ID:
additional_paid_in_capitalHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.64B | $7.09B | $6.88B | $6.93B | $7.10B | $7.23B | $7.39B | $7.22B | $7.37B | $7.34B | $7.45B | $7.28B | $7.10B | $6.91B | $6.67B | $6.17B | $5.99B | $5.01B | $5.12B |
| QoQ Change | — | -7.3% | -2.9% | +0.7% | +2.5% | +1.8% | +2.2% | -2.3% | +2.1% | -0.4% | +1.5% | -2.2% | -2.5% | -2.8% | -3.4% | -7.5% | -3.0% | -16.3% | +2.1% |
| YoY Change | — | — | — | — | -7.1% | +2.0% | +7.3% | +4.2% | +3.8% | +1.6% | +0.9% | +0.9% | -3.6% | -5.9% | -10.4% | -15.3% | -15.7% | -27.4% | -23.3% |
Range$5.01B – $7.64B
CAGR-8.5%
Avg YoY Growth-5.9%
Median YoY Growth-3.6%
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's additional paid-in capital?
- Vertex Pharmaceuticals (VRTX) reported additional paid-in capital of $5.12B in Q4 2025.
- How has Vertex Pharmaceuticals's additional paid-in capital changed year-over-year?
- Vertex Pharmaceuticals's additional paid-in capital decreased by 23.3% year-over-year, from $6.67B to $5.12B.
- What is the long-term trend for Vertex Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's additional paid-in capital has grown at a -8.3% compound annual growth rate (CAGR), from $7.89B to $5.12B.
- What does additional paid-in capital mean?
- Capital contributed by shareholders above the nominal par value of the stock.